Parenteral therapeutic - Accord Healthcare/Ferrer

Drug Profile

Parenteral therapeutic - Accord Healthcare/Ferrer

Latest Information Update: 20 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Accord Healthcare; Ferrer
  • Developer AMRI; Ferrer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 21 Feb 2017 AMRI, Ferrer and Accord Healthcare agree to co-promote and co-develop parenteral therapeutic
  • 21 Feb 2017 Early research in Undefined indication in Spain (Parenteral)
  • 21 Feb 2017 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top